Opportunities for future biological therapy in SLE.
The development of monoclonal antibodies and the emergence of recombinant DNA technology has made it possible to identify and selectively inhibit distinct cell subsets, surface molecules and secreted products that contribute to normal and pathological immune responses. These advances have helped to clarify the mechanisms that promote autoimmune diseases. As a result, it is now possible to contemplate rational strategies for the treatment of these diseases. Some of these strategies are designed to influence the cell surface interactions that determine whether potentially autoreactive T cells become activated or tolerant following antigen stimulation. Other strategies are designed to augment or inhibit distinct cytokines that regulate autoimmunity. All of these strategies have shown promise in animal models for systemic lupus erythematosus, and they may soon be translated into effective new therapies for people.
Wofsy
D
D
Department of Medicine, Department of Veterans Affairs Medical Center, San Francisco, CA 94121, USA.
Daikh
D I
DI
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*
D000911:Antibodies, Monoclonal